Publications And Research

  1. Vishal Gupta et al, Does Sacubitril/Valsartan Combination Therapy Provide Additional

Renal Benefits In Type 2 Diabetes Mellitus, Receiving Canagliflozin? ADA, Virtual

Meeting, 2021 (P-784) (https://diabetes.diabetesjournals.org/content/70/

Supplement_1/784-P)

  1. Vishal Gupta et al: A Case Series of Hypopituitarism Presenting As Nocturnal

Hypoglycaemia In Patients With Type 2 Diabetes Mellitus, Poster, ECE 2020 Sept

(virtual meeting) (https://www.endocrine-abstracts.org/ea/0070/ea0070ep305)

  1. Vishal Gupta et al: To compare the efficiency of canagliflozin (C1) 100mg Vs

canagliflozin (C3) 300mg on vascular protection (hs-CRP), ADA, Chicago, 2020

(Pub-2219) (https://diabetes.diabetesjournals.org/content/69/Supplement_1/2219-

PUB)

  1. Vishal Gupta et al: Effect of sacubitril/Valsartan combination therapy in type 2

diabetes mellitus patients with elevated NT-ProBNP & preserved ejection fraction

ADA, Chicago, Virtual meeting, 2020 (P-1069) (https://diabetes.diabetesjournals.org/

content/69/Supplement_1/1069-P)

  1. Vishal Gupta et al; “To evaluate the relationship between HSCRP and NT-proBNP in 200

type 2 diabetes patients optimised for conventional cardiovascular and renal risk

factors at the end of 2 years, Submission-Number: A-19-346-EASD, Barcelona Sept

2019 (https://www.easd.org/virtualmeeting/home.html#!resources/to-evaluate-the

relationship-between-hscrp-and-nt-probnp-in-200-type-2-diabetes-patients-optimised

for-conventional-cardiovascular-and-renal-risk-factors-at-the-end-of-2-years

b69358fa-782f-4b5f-b5bc-f5514587d5e7)

  1. Dr. Vishal Gupta et al, Canagliflozin may Offer Vascular and Renal Protection in

Patients with Type 2 Diabetes Mellitus- An Indian Perspective. Indian Journal of

Cardiology. Photon, 2019, 112, 145- 165 (https://sites.google.com/site/

internationalindexing/canagliflozin-may-offer-vascular-and-renal-protection-in

patients-with-type-2-diabetes-mellitus–an-indian-perspective-by-dr-vishal-gupta-dr

vaishali-teli-prof-dr-altaf-patel)

  1. Vishal Gupta et al; Comparison of Cardiovascular (NT-ProBNP) and Renal Biomarkers in

280 T2DM Patients with Microalbuminuria vs. Normoalbuminuria, ADA, June 2019,

Diabetes P-4962 (Pub) (https://diabetes.diabetesjournals.org/content/68/

Supplement_1/2229-PUB?

utm_source=TrendMD&utm_medium=cpc&utm_campaign=Diabetes_TrendMD_0)8. Vishal Gupta et al; Despite Optimal Use of Angiotensin Receptor Blockers There Exists

Substantial Cardiovascular Risk as Suggested by Elevated NT-ProBNP in 259 T2DM

Patients, ADA,June 2019, Diabetes, 2210 (Pub) (https://

diabetes.diabetesjournals.org/content/68/Supplement_1/2210-PUB?

utm_source=TrendMD&utm_medium=cpc&utm_campaign=Diabetes_TrendMD_0)

  1. Vishal Gupta et al;Effect of High Dose vs. Conventional Dose Angiotensin Receptor

Blockers in 175 T2DM with Microalbuminuria on CV (NT-ProBNP) and Renal Biomarkers ,

ADA,June 2019, 1125-P (Poster) (https://diabetes.diabetesjournals.org/content/68/

Supplement_1/1125-P?

utm_source=TrendMD&utm_medium=cpc&utm_campaign=Diabetes_TrendMD_0)

10.Vishal Gupta et al;, Comparison of Telmisartan vs. Valsartan on Cardiovascular and

Renal Biomarkers in 84 Patients with T2DM with Microalbuminuria, ADA, June 2019,

1126-P (poster) (https://diabetes.diabetesjournals.org/content/68/

Supplement_1/1126-P?

utm_source=TrendMD&utm_medium=cpc&utm_campaign=Diabetes_TrendMD_0)

11.Vishal Gupta et al; N-Terminal pro-B-type Natriuretic Peptide (NT-pro BNP) is a Strong

Predictor of Cardiovascular Risk in Patients with Type 2 Diabetes Optimised for

Conventional Cardiovascular and Renal Risk Factor, And Its Relationship With Highly

Sensitive C-Reactive Protein (Hs-CRP) At The End Of 2 Years, Indian Journal of

Cardiology Photon, 2019, 112, 130-144 (https://sites.google.com/site/

internationalindexing/n-terminal-pro-b-type-natriuretic-peptide-nt-pro-bnp-is-a

strong-predictor-of-cardiovascular-risk-in-patients-with-type-2-diabetes-optimized

for-conventional-cardiovascular-and-renal-risk-factor-and-its-relationship-with-highly

sensitive-creactive-protein-hs-crp-at-the-end-of-2-years)

12.Vishal Gupta et al; An Observational Study To Evaluate Change In Dose Requirement

Of Standard Glucose Lowering, Lipid Lowering And Anti-hypertensive Therapy Treated

With SGLT2-inhibitor (Canagliflozin) Over One Year, In Fifty T2DM Patients, ADA, June

2018, P-1165, Orlando. (https://diabetes.diabetesjournals.org/content/67/

Supplement_1/1165-P)

13.Vishal Gupta et al; To Evaluate Patient Characteristics In Those With Elevated NT

proBNP In Type 2DM patients Optimisation For Conventional CV Risk Factors On

Standard Care For 2 Years, ADA, June 2018, P-1516, Orlando (https://

diabetes.diabetesjournals.org/content/67/Supplement_1/1516-P)

  1. Vishal Gupta et al; The Role Of NT-proBNP As A Biomarker In Evaluating Residual

Cardiovascular Risk In 200 Type 2 DM Patients Optimised For Conventional CV Risk Marker Over 2 years, ADA, June 2018, P- 1513, Orlando (https://

diabetes.diabetesjournals.org/content/67/Supplement_1/1513-P)

15.Vishal Gupta; Michael Willis et al ; Long-term Clinical Benefits of Canagliflozin 100

mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately

Controlled With Metformin in India, Value in Health Regional Issues, Volume 18 , 65 –

73 (https://pubmed.ncbi.nlm.nih.gov/30502662/)

16.Gupta V, et al. Sodium-glucose cotransporter-2 inhibitors: Moving beyond the

glycemic treatment goal. Indian J Endocr Metab 2017;21:909-18. (https://

pubmed.ncbi.nlm.nih.gov/29285458/)

17.Gupta V, Teli V, Subgroup analysis to evaluate effects of baseline characteristics on

markers of renal and cardiovascular risk in type 2 diabetes patients treated with

SGLT2 inhibitor (canagliflozin), published abstract (P2418-PUB) at American Diabetes

Association 2017, San Diego, USA

18.Teli V, Gupta V; A real life prospective study to evaluate effect of sodium-glucose co

transporter-2 inhibitor (canagliflozin) therapy on cardiovascular and renal markers in

patients with type 2 diabetes mellitus, Poster session (P1204) at American Diabetes

association 2017, San Diego,USA

19.Gupta V et al; An analysis of the cost-effectiveness of switching from biphasic human

insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart

30 in people with type 2 diabetes, J Med Econ. 2015 Apr;18(4):263-72 (https://

pubmed.ncbi.nlm.nih.gov/25426701/)

20.Gupta V et al; predictive and explanatory factors of change in health related quality

of life after starting insulin analogs, ADA abstract, June 2015

  1. Gupta V et al; Pituitary apoplexy presenting as myocardial infarction. Indian J

Endocr Metab 2014; 18:232-3 (https://pubmed.ncbi.nlm.nih.gov/24741524/)

22.Asrul Akmal Shafie, Vishal Gupta et al; An analysis of the short- and long-term cost

effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly

controlled type 2 diabetes; diabetes research and clinical practice , 2014, 106, 319–

327 (https://pubmed.ncbi.nlm.nih.gov/25305133/)

23.Gupta V. Normocalcemic primary hyperparathyroidism in a patient with severe

osteoporosis receiving teriparatide. Indian J Endocr Metab 2013;17:336-8 (https://

www.ncbi.nlm.nih.gov/pmc/articles/PMC3683218/)

24.Cheng ML, Gupta V. Premenopausal osteoporosis. Indian J Endocr Metab

2013;17:240-4 (https://pubmed.ncbi.nlm.nih.gov/23776895/)25.Gupta V; Simultaneous presentation of giant pheochromocytoma, primary

hyperparathyroidism, and mixed-medullary-papillary thyroid cancer in MEN 2A. Indian

J Endocr Metab, 2013;17:751-5. (https://pubmed.ncbi.nlm.nih.gov/23961501/)

26.Vishal Gupta; “GLP-1 analogues – a review”; Indian J Endocrinol Metab. 2013 May

Jun; 17(3): 413–421. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712370/)

27.Talwalkar P G, Gupta V, et al; Clinical experience with insulin detemir, biphasic

insulin aspart and insulin aspart in people with type 2 diabetes: Results from the

Mumbai cohort of the A 1 chieve study. Indian J Endocr Metab, 2013, S2:516-20.

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872902/)

  1. Kalra S, Gupta V. The diversity of diabetes. In: Bajaj S, ed. ESI Manual of Clinical

Endocrinology. Hyderabad, Endocrine Society of India, 2012. pp 3-5.

29.Gupta V, Lee M, Growth hormone in chronic renal disease; Indian J Endocr Metab;

2012;16:195-203 (https://pubmed.ncbi.nlm.nih.gov/22470855/)

30.Gupta V. Vitamin D: Extra-skeletal effects. J Med Nutr Nutraceut 2012;1:17-26

(https://www.jmnn.org/article.asp?

issn=2278-1870;year=2012;volume=1;issue=1;spage=17;epage=26;aulast=Gupta)

31.Gupta V, Pleiotropic effects of incretins. Indian J Endocr Metab 2012;16:47-56

(https://pubmed.ncbi.nlm.nih.gov/22701844/)

32.Gupta V, Shah MA, Shah SK, Shah JM. Osteoanabolics. Indian J Endocr Metab

2012;16:349-57 (https://www.ijem.in/article.asp?

issn=2230-8210;year=2012;volume=16;issue=3;spage=349;epage=357;aulast=Gupta;typ

e=0)

33.Cheng ML, Gupta V. Teriparatide – Indications beyond osteoporosis. Indian J Endocr

Metab 2012;16:343-8 (https://pubmed.ncbi.nlm.nih.gov/22629497/)

34.Gupta V, Patil S, Shah D. Primary hyperparathyroidism associated with vitamin D

toxicity in a patient with severe osteoporosis receiving teriparatide. Indian J Endocr

Metab 2012;16:863-4 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475930/)

35.Gupta V; Block and replace therapy using propylthiouracil and levothyroxine for

Graves’ disease during pregnancy, Indian J Endocrinol Metab. 2012 Jul-Aug; 16(4): 660–

  1. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401781/)

36.Vishal Gupta et al, “Idiopathic Granulomatous Hypophysitis Presenting As

Panhypopituitarism”, The Endocrinologist, Vol 20(3), May/June 2010, pp 102-104

37.Vishal Gupta et al ; “Acromegaly Associated With Symptomatic Rathke’s Cyst”, Indian

Journal of Endocrinology and Metabolism; April-Jun 2011, Vol 15, Issue 2. (https://

www.ncbi.nlm.nih.gov/pmc/articles/PMC3125006/)38.Vishal Gupta et al, “Central Hypothyroidism – A Review”, Indian Journal of

Endocrinology and Metabolism, 2011,15, Issue 6 [p. 99-106] (https://

pubmed.ncbi.nlm.nih.gov/21966662/)

39.Vishal Gupta “Adult Growth Hormone Deficiency – A Review”, Indian Journal of

Endocrinology and Metabolism; 2011,15, Issue:7 [p197-202] (https://

pubmed.ncbi.nlm.nih.gov/22029024/)

40.Vishal Gupta el al; “Choosing A Gliptin”, Indian Journal Of Endocrinology and

Metabolism; 2011; 15; Issue : 4, [p298-308] (https://pubmed.ncbi.nlm.nih.gov/

22029001/)

41.Vishal Gupta “Mineralocorticoid Hypertension – A Review”, Indian J Endocr Metab;

2011; 15 ; Issue : 8; Page : 298- 302. (https://www.ijem.in/article.asp?

issn=2230-8210;year=2011;volume=15;issue=8;spage=298;epage=312;aulast=Gupta)

42.Vishal Gupta et al, “Parathyroid Storm Secondary To Parathyroid Adenoma Presenting

With Necrotizing Pancreatitis”, The Endocrinologist, Jan/Feb 2009 Volume 19 (1)

  1. Gestational Diabetes – poster presentation Diabetic Medicine, P 305 Supplement

15, 2008-05-02

44.Book chapters

  • Editor in Chief for textbook titled: “Type 2 diabetes and beyond”, Jaypee

Brother Publishing Company, Published March 2021. (http://

www.jpmedpub.com/bookdetails.aspx?CatID=37&OBookID=3213)

Author of the following chapters/sections:

  1. Gupta V; “From hyperglycaemia, to defining type 2 diabetes mellitus”; ed: Beyond

Type 2 Diabetes Mellitus: First Edition; Jaypee publishing house, 2021, Page 1-16

  1. Gupta V; “Does it boil down to insulin resistance versus beta cell failure, Focus on

Pathophysiology and Co-relation to therapeutics”, ed: Beyond Type 2 Diabetes

Mellitus: First Edition; Jaypee publishing house, 2021, Page 17-120

  1. Gupta V; “Beyond Diabetic dyslipidemia”, ed: Beyond Type 2 Diabetes Mellitus: First

Edition; Jaypee publishing house, 2021, Page 121-147

  1. Gupta V; “Unmet need in cardiovascular mortality Va- Hypertension, Vb – coronary

heart disease, Vc – heart failure, Vd – stroke; ed: Beyond Type 2 Diabetes Mellitus:

First Edition; Jaypee publishing house, 2021, Page 161-245

  1. Gupta V; The reality behind assessing renal function” ed: Beyond Type 2 Diabetes

Mellitus: First Edition; Jaypee publishing house, 2021, Page 246-284.

  1. Gupta V; “Diabetes and risk to cancer” ed: Beyond Type 2 Diabetes Mellitus: First

Edition; Jaypee publishing house, 2021, Page 285-308G. Kapadia A, Gupta V; “Autoimmune associations with type 2 diabetes mellitus”, ed:

Beyond Type 2 Diabetes Mellitus: First Edition; Jaypee publishing house, 2021, Page

309-340

  1. Gupta V; “Type 2 Diabetes mellitus, Immunity and infection”, First Edition; Jaypee

publishing house, 2021, Page 341-382

  1. Gupta K, Gupta V; Role of diet, does it matter?”, First Edition; Jaypee publishing

house, 2021, Page 383-406

45.Gupta V; GLP-1 analogues and Insulin Combination, Kalra S et al ed: Incretin based

therapies: First Edition; Jaypee publishing house, 2013, p50-57

  1. Gupta V; Pleiotropic effects of incretins; cardiovascular effects, Kalra S et al ed:

Incretin based therapies: First Edition; Jaypee publishing house, 2013, p103

  1. Gupta V; Pleiotropic effects of incretins; neurological effects, Kalra S et al ed:

Incretin based therapies: First Edition; Jaypee publishing house, 2013, p113

  1. Gupta V; Pleiotropic effects of incretins; gastrointestinal and hepatobiliary effects,

Kalra S et al ed: Incretin based therapies: First Edition; Jaypee publishing house,

2013, p117

  1. Gupta V; Pleiotropic effects of incretins; insulin sensitivity, Incretin based therapies:

First Edition; Jaypee publishing house, 2013, p123

  1. Gupta V; Pleiotropic effects of incretins; obesity, Kalra S et al ed: Incretin based

therapies: First Edition; Jaypee publishing house, 2013, p131

  1. Gupta V; choosing a DPP-4 inhibitor, Kalra S et al ed: Incretin based therapies: First

Edition; Jaypee publishing house, 2013, p103